| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1822 | 2021 |
| Timing of antiretroviral therapy for HIV-1 infection and tuberculosis DV Havlir, MA Kendall, P Ive, J Kumwenda, S Swindells, SS Qasba, ... New England Journal of Medicine 365 (16), 1482-1491, 2011 | 732 | 2011 |
| Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 S Naggie, C Cooper, M Saag, K Workowski, P Ruane, WJ Towner, ... New England Journal of Medicine 373 (8), 705-713, 2015 | 569 | 2015 |
| Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 DL Wyles, PJ Ruane, MS Sulkowski, D Dieterich, A Luetkemeyer, ... New England Journal of Medicine 373 (8), 714-725, 2015 | 520 | 2015 |
| Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ... Annals of internal medicine 165 (9), 625-634, 2016 | 423 | 2016 |
| Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection MS Sulkowski, S Naggie, J Lalezari, WJ Fessel, K Mounzer, M Shuhart, ... Jama 312 (4), 353-361, 2014 | 344 | 2014 |
| Postexposure doxycycline to prevent bacterial sexually transmitted infections AF Luetkemeyer, D Donnell, JC Dombrowski, S Cohen, C Grabow, ... New England Journal of Medicine 388 (14), 1296-1306, 2023 | 171 | 2023 |
| Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study JK Rockstroh, K Lacombe, RM Viani, C Orkin, D Wyles, AF Luetkemeyer, ... Clinical Infectious Diseases 67 (7), 1010-1017, 2018 | 159 | 2018 |
| Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study D Wyles, N Bräu, S Kottilil, ES Daar, P Ruane, K Workowski, ... Clinical Infectious Diseases 65 (1), 6-12, 2017 | 159 | 2017 |
| Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, ... The Lancet Respiratory Medicine 9 (12), 1365-1376, 2021 | 149 | 2021 |
| Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata G Chamie, A Luetkemeyer, M Walusimbi-Nanteza, A Okwera, CC Whalen, ... The International journal of tuberculosis and lung disease 14 (10), 1295-1302, 2010 | 143 | 2010 |
| Optimizing hydroxychloroquine dosing for patients with COVID‐19: an integrative modeling approach for effective drug repurposing M Garcia‐Cremades, BP Solans, E Hughes, JP Ernest, E Wallender, ... Clinical Pharmacology & Therapeutics 108 (2), 253-263, 2020 | 136 | 2020 |
| Doxycycline prophylaxis for bacterial sexually transmitted infections JS Grant, C Stafylis, C Celum, T Grennan, B Haire, J Kaldor, ... Clinical Infectious Diseases 70 (6), 1247-1253, 2020 | 120 | 2020 |
| All-oral therapy with sofosbuvir plus ribavirin for the treatment of Hcv Genotype 1, 2, and 3 infection in patients co-infected with Hiv (photon-1): 212 MS Sulkowski, M Rodriguez-Torres, JP Lalezari, JW Fessel, K Mounzer, ... Hepatology 58, 313A-314A, 2013 | 103 | 2013 |
| Evaluation of Xpert MTB/RIF versus AFB smear and culture to identify pulmonary tuberculosis in patients with suspected tuberculosis from low and higher prevalence settings AF Luetkemeyer, C Firnhaber, MA Kendall, X Wu, GH Mazurek, ... Clinical infectious diseases 62 (9), 1081-1088, 2016 | 101 | 2016 |
| Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens DL Wyles, AF Luetkemeyer Topics in antiviral medicine 25 (3), 103, 2017 | 96 | 2017 |
| Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, ... The lancet respiratory medicine 10 (9), 888-899, 2022 | 94 | 2022 |
| Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV–TB programs AF Luetkemeyer, MA Kendall, M Nyirenda, X Wu, P Ive, CA Benson, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 65 (4), 423-428, 2014 | 92 | 2014 |
| Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus PE Sax, JK Rockstroh, AF Luetkemeyer, Y Yazdanpanah, D Ward, ... Clinical Infectious Diseases 73 (2), e485-e493, 2021 | 83 | 2021 |
| Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group … AF Luetkemeyer, SL Rosenkranz, D Lu, F Marzan, P Ive, E Hogg, ... Clinical infectious diseases 57 (4), 586-593, 2013 | 77 | 2013 |
